| Patient | Hubert H. Humphrey |
|---|---|
| Date of birth | 1960-05-27 |
| Identifiers | MRN HR-ML022-SYN; SSN (made up) 000-22-8047 |
| Document date | 2026-07-07 |
| Author | Walter Brandvold, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Nine-month follow-up after cystectomy; acid-base on sodium bicarbonate. [S]
Mr. Humphrey returns three months after his last visit, nine months after his operation and five weeks after his annual wellness visit. He takes sodium bicarbonate twice a day without stomach upset, and the late-afternoon tiredness has gone. He has had no fever, flank pain, or further infection, and no leaks; he changes the appliance every four days. He has had no bone pain, cough, weight loss, change in bowel habit, or rectal bleeding. He works full time and walks 30 minutes most days. [S]
| Element | Detail |
|---|---|
| Acidosis | Tiredness resolved on sodium bicarbonate |
| Stoma | No leaks; skin healthy |
| Recurrence symptoms | None |
| Function | Working full time; walking daily |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy back to normal; weight up; no fever |
| Genitourinary | Negative | Clear urine; no flank pain |
| Gastrointestinal | Negative | No stomach upset on bicarbonate; no change in bowel habit or bleeding |
| Musculoskeletal | Negative | No bone pain |
| Respiratory | Negative | No cough |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sodium bicarbonate 650 mg oral tablet, one tablet by mouth twice daily, for metabolic acidosis after an ileal conduit | One tablet twice daily | Oral route | 2026-04-07 | active | S |
| Ciprofloxacin 500 mg oral tablet, one tablet by mouth twice daily for 7 days, for acute pyelonephritis | One tablet twice daily for 7 days | Oral route | 2026-03-17 to 2026-03-23 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-07 | Body height | 180 | cm | S |
| 2026-07-07 | Body weight | 78.8 | kg | S |
| 2026-07-07 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 2026-07-07 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-07 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-07 | Heart rate | 70 | /min | S |
| 2026-07-07 | Respiratory rate | 14 | /min | S |
| 2026-07-07 | Body temperature | 36.7 | Cel | S |
| 2026-07-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-07 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-07-07 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-07 | Chloride [Moles/volume] in Serum or Plasma | 106 | mmol/L | 98-107 mmol/L | Normal | S |
| 2026-07-07 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-07-07 | Urea nitrogen [Mass/volume] in Serum or Plasma | 17 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-07-07 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-07 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 74 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-07 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-07-07; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Abdomen | Soft and non-tender; no masses; no hernia |
| Stoma | Pink and moist; peristomal skin healthy |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Urothelial carcinoma of the bladder, multifocal, with carcinoma in situ, pT2a pN0 (0 of 18 nodes), margins negative, treated by radical cystoprostatectomy with an ileal conduit; no evidence of disease; under surveillance; synthetic modern detail linked to his documented bladder cancer | active | confirmed | Z85.51 | S — Synthetic grade, stage, node count, and margins; the bladder growths, the earlier thiotepa and X-ray therapy, the low-grade malignancy, and the radical cystectomy with a small-intestine conduit are documented (D). Z85.51 is used because the tumor has been removed and no further treatment is directed at it. |
| Ileal conduit urostomy, right lower abdomen | active | confirmed | Z93.6 | S — The small-intestine conduit and the stoma to the right of the navel are documented (D); the coding and the stoma findings are synthetic. |
| Acquired absence of the bladder and part of the urethra after radical cystectomy | active | confirmed | Z90.6 | S — Documented operation (D); synthetic coding. |
| Acquired absence of the prostate after cystoprostatectomy | active | confirmed | Z90.79 | S — Documented operation (D); synthetic coding. |
| Personal history of pelvic radiation for bladder tumor, with earlier intravesical thiotepa | active | confirmed | Z92.3 | S — The thiotepa and X-ray therapy are documented (D); the coding and their relevance to the modern episode are synthetic. |
| Hyperchloremic metabolic acidosis from the ileal conduit, mild | active | confirmed | E87.22 | S — Synthetic finding at the six-month visit, a known effect of urine contact with the ileal segment. |
| Acute right pyelonephritis with an ileal conduit (Escherichia coli), with mild acute kidney injury, treated with oral ciprofloxacin and resolved | resolved | confirmed | N10 | S — Synthetic intercurrent infection at an unscheduled visit, a common complication of an ileal conduit; it does not echo a documented illness of his after the operation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Chemistry with creatinine, chloride, and bicarbonate | Every 3 to 6 months in the first year after diversion, then yearly | Completed today | Creatinine 1.10 mg/dL, eGFR 74; chloride 106, bicarbonate 24 mmol/L on treatment |
| Laboratory | Vitamin B12 | Yearly from two to three years after an ileal diversion | Up to date | Baseline normal six months ago |
| Imaging | CT of the chest, abdomen, and pelvis (with urographic phase) | Every 6 to 12 months for 2 to 3 years after cystectomy, then yearly | Due | At one year after surgery, in three months; the urographic phase covers the upper tracts |
| Imaging | Upper-tract imaging (renal ultrasound or CT urography) | Every 6 months to year 3, then yearly | Up to date | Renal ultrasound three months ago without hydronephrosis; next with the CT |
| Examination | Stoma and peristomal skin | Every visit | Completed today | Healthy |
| Examination | Parastomal and incisional hernia | Every visit | Completed today | None |
| Medication safety | Sodium bicarbonate: tolerance and sodium load | Every visit on alkali therapy | Completed today | No bloating; blood pressure 128/76 mm Hg; no edema |
| Survey | Distress and depression screen (PHQ-2) | Every visit | Completed today | PHQ-2 score 0 |
| Laboratory | Routine urine culture of conduit urine | Only for fever, flank pain, or other signs of infection | Not indicated | Bacteria are expected in conduit urine; no symptoms today |
| Laboratory | Urethral wash cytology | Periodically if the urethra is retained and at high risk | Not indicated | Urethral margin negative and no prostatic urethral involvement |
| Self-management | Survivorship care plan, fluid intake, and activity | After treatment; fluids and activity every visit | Completed today | Written plan given; about 2 liters of fluid a day; walking 30 minutes most days |
Goal progress:
Guideline basis: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026)
Follow-up: CT and urology review in three months, at one year after surgery. Primary care at the same time with chemistry. [S]